SeQuent Scientific Limited (SeQuent), announced launch of Halofusol ® 0.5 mg/ml Oral Solution for Calves in 19 European countries. The product had recently received approval from the European Medicines Agency (EMA) through its Spanish subsidiary Laboratorios Karizoo, S.A.
The product was developed at SeQuent's R&D centre at Barcelona, Spain & will be manufactured in Spain. The approval follows the recent approval of Tulathromycin, both of which were approved within 12 months of filing, reflecting of SeQuent's growing strength in product development for the regulated markets.
Halofusol® offers superior value for farmers with user-friendly and cost-effective drug delivery system.
Halofusol is an oral antiprotozoal solution for the prevention and reduction of diarrhoea in new-born calves, diagnosed with Cryptosporidium parvum and is a generic version of Halocur (Innovator: Merck Animal Health) with market size of ~Euro 10Mn in EU. SeQuent is also planning to extend the launch to other geographies.
Shares of SEQUENT SCIENTIFIC LTD. was last trading in BSE at Rs.155.9 as compared to the previous close of Rs. 153.2. The total number of shares traded during the day was 40225 in over 739 trades.
The stock hit an intraday high of Rs. 157.55 and intraday low of 153.8. The net turnover during the day was Rs. 6267872. |
